Neha K. Reddy, MD MA

Heme/Onc Fellow @NorthwesternMed via @DellMedIntMed @NUFeinbergMed | she/her/hers

[Christopher Fitzmaurice, MS, CEP, CSCS @ChristopherACSM]

The many reasons why exercise is great against cancer. Whether the effects or direct or indirect, exercise is medicine regardless.

https://t.co/4yDn20TvGB

#exerciseismedicine #exercise #oncology #cancer #prevention #treatment #exercisephysiologist #exercisephysiology #exerciseoncology #exerciseoncologist #movement #exercisetherapy #clinicalexercisephysiologist #clinicalexercisephysiology #physicalactivity #lifestyle #cancertreatment #cancerprevention #oncologist #diagnosis #survivorship #depression #fatigue #qualityoflife #mentalhealth #lymphedema #mastectomy #strengthtraining #resistancetraining #sleep #integrativeoncology #prehab #prehabilitation #rehabilitation #physicaltherapy #physicaltherapist #physiotherapist #health @ACSMNews @CEPAupdates @AmericanCancer

[Erman Akkus @Erman_Akkus]

🧮First-line chemotherapies in advanced pancreatic cancer
@TheLancetOncol

✅Meta-analysis reaffirms NALIRIFOX /FOLFIRINOX as first-line regimens

@TheLancet @OncoAlert @realbowtiedoc #cancer #oncology #MedX

[Vivek Subbiah, MD @VivekSubbiah]

🚨Hot off the press 👉Delighted to share our latest publication👉 "Redefining pancreatic cancer management with tumor-agnostic precision medicine." ⭐️Discover how #PrecisionMedicine & #Tumoragnostic therapies are enhancing outcomes for pancreatic cancer patients.
👉From #KRAS mutations to #NTRK fusions and beyond, these therapies offer new hope.
👏Kudos to @nehakred , a rising star and hematology/oncology fellow at @Luriecancer @NorthwesternU @LeonidasPlatan1 for spearheading this paper -published as part of a special issue edited by Dr. Sharon R. Pine & Dr. David Tuveson at Carcinogenesis @OxUniPress
🙏 @aiims1742 for the invite. @oncoalert @PanCAN
#PrecisionMedicine #Oncology #PancreaticCancer #TumorAgnostic #CancerResearch
Link: https://t.co/0aw5EyeFiC

[Eric K. Singhi, MD @lungoncdoc]

📣 #FLAURA2 results are in!

What is the added benefit of chemotherapy to osimertinib in the 1L setting of EGFR mutant mNSCLC?

Practice-changing? Let’s take a closer look. 🤔

@OncoAlert @IASLC #WCLC23 #lcsm

[Vivek Subbiah, MD @VivekSubbiah]

🚨Hot off the press👉 Presenting a novel resistance mechanism to BRAF+MEK in Glioblastoma
-->Histological transformation to Gliosarcoma + acquisition of oncogenic KRAS G12D+ NF1 L1083R mutation as mechanism of resistance to combined BRAF/MEK inhibition in BRAF V600E mutated glioblastoma 1/3 @BlessieNelson @mgoudaMD @MirellaNardo @nehakred @NaturePortfolio @Nature_NPJ @OncoAlert
https://t.co/dOjvKaOkP3

[Vivek Subbiah, MD @VivekSubbiah]

⭐️Getting ready for #AACR23 @AACR ?
Time to read about 👉 "Top advances of the year in #PrecisionOncology "@JournalCancer @AmericanCancer @ADesaiMD @nehakred @weoncologists @OncoAlert #precisionmedicine
What do you predict will be Top advances for next year ? Some of them will be presented @aacr
https://t.co/odW9SyrJpy

[Vivek Subbiah, MD @VivekSubbiah]

Top advances of the year: Precision oncology @OncoAlert @JournalCancer @ADesaiMD @nehakred https://t.co/bPc5QGj8xD

[Vivek Subbiah, MD @VivekSubbiah]

⭐️Globalizing precision oncology should be a major priority for cancer care in the upcoming decades👉 Think Globally, Act Locally: Globalizing Precision Oncology @JournalCancer #acscancerchat @CD_AACR @ElizSMcKenna @nehakred @ADesaiMD @Aiims1742 @ShaalanBeg @jtmoyers @weoncologists
https://t.co/8mOXUxCy1O

[ACS Journal Cancer @JournalCancer]

That’s a wrap for today’s #ACSCancerChat! Huge thanks to our special guests @VivekSubbiah @nehakred & @ADesaiMD for joining us today. Be sure to download their latest article here: https://t.co/05PGrAHTiT

[Gil Morgan, MD @weoncologists]

Thank you so much @JournalCancer for another wonderful #ACSCancerChat
My thanks to @VivekSubbiah @ADesaiMD and @nehakred and Kudos on their amazing paper!!

https://t.co/kWw46A07sZ

[Vivek Subbiah, MD @VivekSubbiah]

Its about time for #precision #immunotherapy @JournalCancer @ADesaiMD @nehakred @weoncologists @Aiims1742 @ShaalanBeg #acscancerchat

https://t.co/wAhi4RcHbl

[Aakash Desai, MD, MPH, FASCO @ADesaiMD]

@JournalCancer @VSubbiah @nehakred Now it is about ⏲️for 🎯#immunotherapy
💉 #ICI has revolutionized #cancer Rx
🔬 A precision-driven approach in #ICI can identify successful #combinations and improve outcomes for #cancer patients. #ACSCancerChat
@VivekSubbiah https://t.co/vIfGFPOmdQ

[Aakash Desai, MD, MPH, FASCO @ADesaiMD]

@JournalCancer Now it is about ⏲️for 🎯#immunotherapy
💉 #ICI has revolutionized #cancer Rx
🔬 A precision-driven approach in #ICI can identify successful #combinations and improve outcomes for #cancer patients. #ACSCancerChat @VSubbiah @nehakred @JournalCancer https://t.co/vIfGFPOmdQ

[Vivek Subbiah, MD @VivekSubbiah]

Presenting TOP advances in #PrecisionMedicine @JournalCancer @ADesaiMD @weoncologists @Aiims1742 ! #ACScancerchat
Video by incoming hem/onc fellow @nehakred

[Aakash Desai, MD, MPH, FASCO @ADesaiMD]

@JournalCancer @VivekSubbiah @nehakred 👨‍👩‍👧‍👦 Precision-driven cancer therapies offer hope for patients and families facing #cancer

But rising #costs can limit access. 💰

We must continue exploring new Rx/combinations with the HOPE to improve outcomes with therapies that are more accessible. 💪 #ACSCancerChat @VSubbiah

[Vivek Subbiah, MD @VivekSubbiah]

First study showing RET as tissue agnostic target 👉Pan-cancer efficacy of pralsetinib in patients with RET fusion–positive solid tumors from the phase 1/2 ARROW trial @NatureMedicine @JournalCancer #ACScancerchat @ADesaiMD @nehakred https://t.co/jGmz9d2rfl

[Neha K. Reddy, MD MA @nehakred]

@JournalCancer @VivekSubbiah @ADesaiMD In the arsenal against many of these cancers, the utility of our agents is many times unclear to our patients. Families look for objective data to guide their hopes. These advances will help reduce unnecessary side effects from less effective treatments. #ACSCancerChat

[Aakash Desai, MD, MPH, FASCO @ADesaiMD]

@JournalCancer @VivekSubbiah @nehakred @VSubbiah 🎉 Rapid #clinical development has led to targeted agents across various mutational profiles such as #KRASG12C, #Exon20 insertions, and # RET mutations - even those previously considered "undruggable"! @KRASKickers @Exon20Group @RETpositive #ACSCancerChat @VSubbiah @nehakred

[Aakash Desai, MD, MPH, FASCO @ADesaiMD]

@VivekSubbiah @JournalCancer @nehakred @VSubbiah @NEJM For #KRASG12C #LCSM, we now have #Sotorasib
➡️ ORR: 37%, mDOR-11 mths
➡️ mPFS improvement vs docetaxel, although modest- hopefully will lead to improvement over this with upcoming agents/strategies!
and #Adagrasib
➡️ ORR: 43%, mDOR: 9 mths! #ACSCancerChat @VSubbiah @nehakred